Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral SGN1 in Advanced Solid Tumors (Phase I/IIa)
ChiCTR2300078987Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SGN1 in Non-hematologic malignancy, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 10 more, sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate (ORR), Disease control rate (DCR) and 2 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
SGN1
03
Conditions
Non-hematologic malignancysmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR2300078987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078987.